US Corporate Distress Financial Stress SEC Filings — August 27, 2026

Regained Nasdaq compliance on August 25, 2026, after a reverse stock split, with CEO Dominic Wells explicitly attributing the cure to the split. This is a temporary fix; the company remains a micro-cap with no revenue growth or margin improvement data, making it a short-term trading opportunity but a long-term risk [BULLISH (short-term)/BEARISH (long-term)]

Received a second delisting notice for failing the $2.5M stockholders' equity requirement, with no alternative compliance paths available. The company has a cumulative reverse split ratio of 1-for-1100, making it ineligible for a 180-day extension. This is a terminal distress signal

Has 180 days (until Feb 17, 2027) to regain the $1.00 bid price, but as a pre-revenue biotech with no insider buying or positive guidance, the probability of organic recovery is low. The stock is a candidate for a reverse split, which would be a negative signal

Received a third deficiency letter for failing to file two quarterly reports (Q1 and Q2 2026). While the company cured its 10-K delinquency, the pattern of repeated filing failures indicates deep operational and accounting issues. The compliance plan deadline is September 4, 2026, with a final cure date of October 12, 2026

Director Ford Fay resigned effective August 21, 2026, the same day as the additional delisting notice. Insider departures during a compliance crisis are a strong signal of board-level loss of confidence

The company's warrants (ONFOW) trade on Nasdaq, while its preferred stock (ONFOP) trades on OTC. This fragmented listing structure adds complexity and may indicate limited liquidity, a risk for investors seeking to exit [NEUTRAL/BEARISH]

No insider trading activity was reported in the filing, which is notable given the stock is trading below $1.00. The absence of insider buying during a crisis suggests management sees no value at current levels

The company's stock trades under two symbols (SEGG and LTRYW), indicating a complex capital structure with warrants. The dual-ticker structure can create arbitrage opportunities but also signals distress

The company faces simultaneous failures on bid price ($1.00) and equity ($2.5M) requirements, with no path to compliance via market value or net income. The cumulative reverse split ratio of 1-for-1100 over two years is a red flag for shareholder dilution and desperation

Director Ford Fay resigned on the same day as the additional delisting notice. This timing suggests a board-level crisis and potential loss of key governance oversight

The company has received three deficiency letters since April 2026 for late filings. The pattern of non-compliance with SEC reporting requirements indicates systemic accounting or operational failures

As a pre-revenue biotech, Rein has no product sales to support its stock price. With no forward-looking guidance or insider buying, the stock is entirely dependent on speculative catalysts that are not disclosed

The company regained compliance solely through a reverse stock split, which is a cosmetic fix. The CEO's statement that the split allowed the company to 'refocus on growth' does not address the underlying business fundamentals

The delisting stay is contingent on completing a business combination with Clean World Ventures, Inc. If the deal fails, the stock will be delisted immediately on September 15, 2026, creating a binary event

The company must submit a compliance plan by September 4, 2026, and any exception is limited to October 12, 2026. Failure to meet these deadlines will result in delisting, creating a near-term binary risk

The filing explicitly states there is no assurance of additional time beyond the 180-day period. If the stock does not recover organically, a reverse split is likely, which would further depress the stock

The company's regained compliance could trigger a short-term rally as institutional investors who were forced to sell due to compliance rules may re-enter. The stock's 12 consecutive days above $1.00 provides a technical floor

The stock's delisting stay is tied to the Clean World Ventures deal. If the deal closes successfully, the stock could re-rate significantly. The September 15, 2026 deadline creates a defined catalyst window

The company has a track record of curing prior delinquencies (e.g., the 10-K was filed on July 10, 2026). If the company submits a credible compliance plan by September 4, 2026, the stock could see a relief rally

The stock has until February 17, 2027, to regain compliance. If the company announces a positive catalyst (e.g., clinical trial data, partnership), the stock could recover organically. The long timeline provides optionality

The CEO stated the company will refocus on its growth and acquisition strategy. If Onfolio announces a value-accretive acquisition, the stock could gain momentum. The company's warrants (ONFOW) offer leveraged exposure to any upside

The company has until August 28, 2026, to present its views to the Hearing Panel. A compelling presentation could lead to an extended stay or a path to compliance, creating a near-term catalyst

The company successfully cured its 10-K delinquency, demonstrating some ability to resolve reporting issues. If the Q1 and Q2 2026 filings are completed, the stock could recover significantly from distressed levels

As a pre-revenue biotech, Rein likely has minimal debt, reducing the risk of creditor-driven bankruptcy. The company's cash burn rate (not disclosed) is the key variable to monitor

Three of four companies (Lottery.com, SOBR Safe, Rein Therapeutics) are in a multi-stage delisting process, where one deficiency (e.g., bid price) triggers others (e.g., equity, filing). This pattern suggests that micro-cap companies with weak fundamentals often fail to resolve initial compliance issues, leading to a cascade of failures

Both Onfolio Holdings (regained compliance) and SOBR Safe (ineligible for extension due to cumulative splits) demonstrate that reverse splits are a short-term solution. Onfolio's split worked, but SOBR's 1-for-1100 ratio over two years shows that repeated splits destroy shareholder value and eventually close off compliance paths

Across all four filings, there is zero insider trading activity reported. In a normal market, distressed companies often see insider buying as a signal of confidence. The complete absence here suggests management teams are not willing to risk personal capital, a bearish signal for all four names

None of the four companies reported any period-over-period revenue growth or margin expansion. This is consistent with a distress theme where companies are focused on survival (compliance, cash preservation) rather than growth. The lack of operational metrics in the filings is itself a red flag

SOBR Safe (business combination), Lottery.com (compliance plan), and Rein Therapeutics (bid price recovery) are all dependent on single binary events for survival. This creates high-risk, high-reward scenarios where the stock could either rally significantly or go to zero, depending on the outcome

The company must present its views by August 28, 2026. The Hearing Panel's decision on whether to extend the stay beyond September 15, 2026, is a critical binary event. Watch for any press releases or filings regarding the Clean World Ventures deal

The deadline is September 4, 2026. The quality and credibility of the plan will determine whether the stock can avoid delisting. Watch for any auditor changes or management commentary on the filing delays

The stock has 180 days until February 17, 2027. Monitor weekly closing prices for any signs of recovery. A reverse stock split announcement would be a negative signal and should trigger a sell-off

The stock regained compliance on August 25, 2026. Watch for any insider selling in the next 30 days, which would indicate that management used the compliance rally to exit positions. Also monitor for any acquisition announcements

The delisting stay is contingent on closing the Clean World Ventures deal. Any delays or renegotiations of deal terms would be highly negative. The September 15, 2026 deadline is the final catalyst date

The company has two outstanding quarterly reports (Q1 and Q2 2026). Any filing of these reports before the compliance plan deadline would be a strong positive signal. Watch for 8-K filings indicating the reports are complete

The absence of insider buying is notable. Any insider purchases in the next 30 days would be a strong contrarian signal. Conversely, insider selling would confirm the bearish thesis

Following director Ford Fay's resignation, watch for any additional board departures. A mass exodus would signal that the business combination is unlikely to close